Physician profile
Keshav Prasad
NPI 1356379457
$1,022.90
in general payments reported to CMS, 2019-2025
17 companies · $51.86 in 2025
The $51.86 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $76.47 · 2021: $366 · 2022: $108 · 2023: $43.01 · 2024: $171 · 2025: $51.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $203.14 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $172.20 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Horizon Therapeutics Plc | $162.66 | 2019-2023 | Krystexxa |
| Pfizer INC. | $109.07 | 2019-2023 | |
| Astellas Pharma US INC | $76.03 | 2019-2024 | Veozah |
| Novo Nordisk INC | $52.82 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $51.83 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.67 | 2022 | |
| Vanda Pharmaceuticals INC. | $26.84 | 2021-2022 | |
| Array Biopharma INC | $19.12 | 2025 | Lorbrena |
| Otsuka America Pharmaceutical, INC. | $18.30 | 2025 | Jynarque |
| Boston Scientific Corporation | $18.06 | 2019 | |
| Biogen, INC. | $16.07 | 2021 | |
| Kyowa Kirin, INC. | $14.44 | 2025 | |
| Allergan, INC. | $13.40 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.36 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keshav Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.